Literature DB >> 23278563

Epithelial and stromal syndecan-1 and -2 are distinctly expressed in oral- and cutaneous squamous cell carcinomas.

Abdirisak Ahmed Haji Omar1, Caj Haglund, Susanna Virolainen, Valtteri Häyry, Timo Atula, Risto Kontio, Jarmo Rihtniemi, Antti Pihakari, Tuula Salo, Jaana Hagström, Timo Sorsa.   

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) and cutaneous squamous cell carcinoma (CSCC) are epithelial neoplasms of which OSCC has worse survival and higher risk of metastasis than CSCC. The aim of this study was to explore the differences of immunoexpressions between syndecan-1 and -2 in OSCC and head and neck CSCC.
METHODS: A total of 35 patients diagnosed with OSCC and 25 with CSCC, presented T1 and T2 tumors and treated at Helsinki University Central Hospital between years 2001 and 2009, were selected into this study. The levels and locations of syndecan-1 and -2 immunostainings were analyzed using formalin-fixed and paraffin-embedded tissue samples of OSCC and CSCC cases together with clinical data.
RESULTS: Cell membrane epithelial syndecan-1 expression decreased significantly compared to normal tissue in both cancer types. Cell membrane syndecan-1 expression in the invasive front had negative correlation with invasion depth of both tumors (OSCC, r = -0.339, P = 0.025; CSCC, r = -0.469, P = 0.004). In cancers over 4-mm invasion depth, the number of stromal syndecan-1-positive collagen fibers and inflammatory cells were higher in OSCC than in CSCC. Syndecan-2 expression in non-malignant stroma was higher in CSCC than in OSCC tumors. In addition, unlike syndecan-1, syndecan-2 was more often and more intensively expressed in the tumor inflammatory cells in CSCC than in OSCC.
CONCLUSION: Our results suggest that variable stromal expression of syndecan-1 and -2 in OSCC compared to CSCC may at least partially explain the differences in their clinical behavior.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278563     DOI: 10.1111/jop.12025

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

Review 1.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

Review 2.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

Review 3.  Syndecan-1 (CD138), Carcinomas and EMT.

Authors:  John R Couchman
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

4.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

5.  Stromal and epithelial syndecan-1 expression in benign and malignant salivary gland tumors: which is more reflective of behavior?

Authors:  Mojgan Alaeddini; Farzad Yazdani; Shahroo Etemad-Moghadam
Journal:  Braz J Otorhinolaryngol       Date:  2019-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.